Institutional members access full text with Ovid®

Share this article on:

Clinical perspectives on echinocandin resistance among Candida species

Shields, Ryan K.a; Nguyen, M. Honga; Clancy, Cornelius J.a,b

Current Opinion in Infectious Diseases: December 2015 - Volume 28 - Issue 6 - p 514–522
doi: 10.1097/QCO.0000000000000215
ANTIMICROBIAL AGENTS: BACTERIAL/FUNGAL: Edited by Monica A. Slavin
Editor's Choice

Purpose of review: We review and offer our clinical perspectives on the emergence of echinocandin-resistant Candida.

Recent findings: Candida FKS gene mutations attenuate echinocandin activity, but overall mutation rates among clinical isolates remain low (Candida glabrata, ∼4%; other species, <1%). Rates are higher with prior echinocandin exposure, exceeding 50% among C. glabrata or Candida albicans isolates causing breakthrough invasive candidiasis. The median duration of prior echinocandin exposure among FKS mutant isolates is ∼100 days. The clinical usefulness of echinocandin susceptibility testing is limited by the low overall prevalence of resistance, and uncertainties surrounding testing methods and interpretation of minimum inhibitory concentrations (MICs). In single-center studies, caspofungin resistance (defined using institution-specific MIC breakpoints) was 32–53% sensitive and 75–95% specific for predicting treatment outcomes of C. glabrata invasive candidiasis; corresponding values for the presence of an FKS mutation were 35–41% and 90–98%. Results were similar using anidulafungin and micafungin MICs. Clinical data are scarce for non-C. glabrata species.

Summary: Echinocandins remain preferred agents against invasive Candida infections. Susceptibility testing and FKS genotypic testing do not have roles in routine clinical practice, but may be useful in newly-diagnosed patients who are echinocandin-experienced or those who have not responded to echinocandin treatment.

aDepartment of Medicine, University of Pittsburgh

bVA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania, USA

Correspondence to Cornelius J. Clancy, MD, Associate Professor of Medicine, Director, Mycology Research Unit and XDR Pathogen Laboratory, University of Pittsburgh, and Chief, Infectious Diseases Section, VA Pittsburgh Healthcare System, 3550 Terrace Street, S867 Scaife Hall, Pittsburgh, PA 15261, USA. E-mail: cjc76@pitt.edu

Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.